Jean-Michel Carle Grandmougin

Jean-Michel Carle Grandmougin is a Director and General Manager of EUROBIO SCIENTIFIC since 2023. He is in charge of the group's marketing and sales strategy, quality and regulatory issues, as well as sales in France. He was previously President of EUROBIO SCIENTIFIC's Management Board since 2017 and Chairman and CEO of the Group since 2019. He is also President of the EUROBIONEXT holding company which is EUROBIO SCIENTIFIC's reference shareholder.

‍

Jean-Michel Carle Grandmougin has more than 35 years of experience in the field of in vitro diagnostics and research in life sciences. Before becoming a member of the Management Board of the DIAXONHIT Group, he was Chairman and Chief Executive Officer and one of the two partners of the EUROBIO / Capforce Group which was acquired by DIAXONHIT in March 2017. He joined EUROBIO SA in 2006 as Sales Manager and quickly became its Managing Director.

‍

In June 2010, he acquired the company with Denis Fortier and the OTC Asset Management fund which sold back its shares in 2014 to Jean-Michel and Denis. In 1992, he joined BMD (now Theradiag) where he was Sales Director for 13 years before taking responsibility of its German activity. Holder of a bachelor's degree in biology, he began his career in 1985 at Technicon (now Bayer Diagnostics) as a Technical Sales Engineer to become Sales Manager at 30.

‍

Jean-Michel Carle Grandmougin owns approximately 27% of the EUROBIONEXT holding company which holds approximately 30% of EUROBIO SCIENTIFIC's capital.